Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 5, 2011, Pages 276-288

  El Komy, Mohammed H ^a   Schmidt, Robert L ^b   Widness, John A ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

CERA; erythropoiesis stimulating agent (ESA); erythropoietin; pharmacokinetics; physiological model; receptor; receptor binding; recirculation model

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHROPOIESIS; IN VIVO STUDY; INTERNALIZATION; MODEL; NONHUMAN; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; SHEEP;

ANIMALS; ERYTHROPOIETIN, RECOMBINANT; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; PROTEIN BINDING; RECEPTORS, ERYTHROPOIETIN; SHEEP; UP-REGULATION;

EID: 79959721538     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.757     Document Type: Article

References (42)

1. Koury MJ, Bondurant MC,. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 1988; 137: 65-74. doi: 10.1002/jcp.1041370108
2. Lacombe C, Mayeux P,. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14 (Suppl 2): 22-28. (Pubitemid 29154936)
3. Remy I, Wilson IA, Michnick SW,. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283: 990-993.
4. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P,. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005; 105: 600-608. 10.1182/blood-2004-03-1216 (Pubitemid 40070742)
5. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y,. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283: 520-527. (Pubitemid 27514606)
6. Kato M, Miura K, Kamiyama H, et al,. Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metab Dispos 1998; 26: 126-131. (Pubitemid 28104079)
7. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS,. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 1999; 20: 217-223. doi: 10.1002/(SICI)1099-081X(199905)20: 4<217::AID-BDD177>3.0.CO;2-6 [pii] (Pubitemid 29363908)
8. Yoon WH, Park SJ, Kim IC, Lee MG,. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 1997; 96: 227-240. (Pubitemid 27287775)
9. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS,. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-767.
10. Brandt M, Lanzendorfer M, Frische J, Haselbeck A, Jarsch M,. Different receptor binding activity of CERA (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transpl 2006; 21: 9-9.
11. Macdougall IC, Robson R, Opatrna S, et al,. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215. doi: Doi 10.2215/Cjn.00730306
12. Klinger M, Arias M, Vargemezis V, et al,. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50: 989-1000. doi: S0272-6386(07)01197-3 [pii] 10.1053/j.ajkd.2007.08.013 (Pubitemid 350122810)
13. Sulowicz W, Locatelli F, Ryckelynck JP, et al,. Investigators PS. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-646. doi: Doi 10.2215/Cjn.03631006
14. Haselbeck A, Tare N, Pill J,. Pre-clinical pharmacokinetics and pharmacodynamics of CERA (continuous erythropoiesis receptor activator) indicate a superior new therapy for anemia. Blood 2002; 100: 228a-228a.
15. Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA,. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of CERA and erythropoietin. J Pharm Pharmacol 2008; 60: 1321-1334. doi: DOI 10.1211/jpp/60.10.0008
16. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A,. Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008; 81: 63-69. doi: Doi 10.1159/000109166 (Pubitemid 350124538)
17. Veng-Pedersen P, Widness JA, Wang J, Schmidt RL,. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J Pharmacokinet Biopharm 1997; 25: 569-593. (Pubitemid 28355711)
18. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, Sawyer ST,. A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med 1992; 119: 285-294.
19. El-Komy MH, Widness JA, Veng-Pedersen P, (in press). Pharmacokinetic analysis of CERA disposition using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos 2011; 39: 603-609.
20. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532. (Pubitemid 34289541)
21. Mager DE, Krzyzanski W,. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005; 22: 1589-1596. doi: 10.1007/s11095-005-6650-0 (Pubitemid 41355898)
22. Hutchinson MF, de Hoog FR,. Smoothing noisy data with spline functions. Numerische Mathematik 1985; 47: 99-106.
23. Upton RN,. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J Pharmacol Toxicol Methods 2008; 58: 198-205. doi: S1056-8719(08)00182-2 [pii] 10.1016/j.vascn.2008.08.001
24. Veng-Pedersen P,. Curve fitting and modeling in pharmacokinetics and some practical experiences with Nonlin and a new program Funfit. J Pharmacokinet Biopharm 1977; 5: 513-531.
25. Clewell HJ, 3rd, Lee TS, Carpenter RL,. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal 1994; 14: 521-531. (Pubitemid 24300016)
26. Licata AC, Dekant W, Smith CE, Borghoff SJ,. A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. Toxicol Sci 2001; 62: 191-204. (Pubitemid 32707733)
27. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA,. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001; 298: 820-824. (Pubitemid 32673436)
28. Veng-Pedersen P, Chapel S, Al-Huniti NH, et al,. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004; 25: 149-156. doi: 10.1002/bdd.395 (Pubitemid 38765288)
29. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P,. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther 2010; 333: 528-532. doi: [pii] 10.1124/jpet.109. 163568
30. Widness JA, Veng-Pedersen P, Schmidt RL, Lowe LS, Kisthard JA, Peters C,. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 1996; 279: 1205-1210.
31. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B,. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007; 47: 1390-1397. doi: 10.1177/0091270007307570 (Pubitemid 47624598)
32. Kupcova V, Sperl J, Pannier A, Jordan P, Dougherty FC, Reigner B,. The effect of severe hepatic impairment on the pharmacokinetics and haematological response of CERA. Curr Med Res Opin 2008; 24: 1943-1950. doi: 10.1185/03007990802176467
33. Kendall RG, Chapman C, Hartley AE, Norfolk DR,. Storage and preparation of samples for erythropoietin radioimmunoassay. Clin Lab Haematol 1991; 13: 189-196.
34. Broudy VC, Nakamoto B, Lin N, Papayannopoulou T,. Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines. Blood 1990; 75: 1622-1626. (Pubitemid 20145747)
35. Grossi A, Vannucchi AM, Bacci P, et al,. Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. Leuk Res 1998; 22: 145-151. doi: S0145212697001343 [pii] (Pubitemid 28185345)
36. Li Y, Lu Z, Keogh CL, Yu SP, Wei L,. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007; 27: 1043-1054. doi: 9600417 [pii] 10.1038/sj.jcbfm.9600417 (Pubitemid 46659037)
37. Panchapakesan U, Sumual S, Pollock C,. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (continuous erythropoietin receptor activator). Int J Nanomed 2007; 2: 33-38. (Pubitemid 46901779)
38. Gross AW, Lodish HF,. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006; 281: 2024-2032. doi: DOI 10.1074/jbc.M510493200 (Pubitemid 43845790)
39. Elliott S, Pham E, Macdougall IC,. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573-1584. doi: S0301-472X(08)00388-3 [pii] 10.1016/j.exphem.2008.08.003
40. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA,. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299. doi: S0301472X03000067 [pii] (Pubitemid 36407605)
41. Sawyer ST, Krantz SB, Goldwasser E,. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid-cells. J Biol Chem 1987; 262: 5554-5562.
42. Fraser JK, Lin FK, Berridge MV,. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol 1988; 16: 836-842.